Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
Upstream Bio announced positive Phase 2 VIBRANT trial data for verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma. The drug demonstrated statistically significant and clinically meaningful improvements in asthma symptom control, reductions in nasal polyp scores, and decreased reliance on corticosteroids…